Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines
Authors: Johanna Chapin-Bardales, PhD, MPH1; Julianne Gee, MPH1; Tanya Myers, PhD, MSc1 In December 2020, 2 mRNA-based COVID-19 vaccines (Pfizer-BioNTech and Moderna) were granted Emergency Use Authorization by the US Food and Drug Administration as 2-dose series and…[...]
Read More